Form 4: Revolution Medicines CEO Sells Shares for Tax Obligations Under Pre-Arranged Plan

Revolution Medicines, Inc. CEO Mark A. Goldsmith sold 13,496 shares of common stock for $39.83 per share on June 16, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer, Director, and a 10% Owner of Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• On June 16, 2025, Mr. Goldsmith disposed of 13,496 shares of RVMD common stock.
• The shares were sold at a weighted average price of $39.83 per share, with individual trades ranging from $39.6016 to $39.8291.
• This transaction was executed under a Rule 10b5-1 plan adopted on May 31, 2023, specifically to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Mr. Goldsmith directly beneficially owns 428,720 shares of common stock, which includes 218,188 RSUs and 652 shares acquired under the Employee Stock Purchase Plan on May 31, 2025.
• Additionally, Mr. Goldsmith indirectly holds 20,424 shares through the Jonathan Goldsmith Revocable Trust, 20,424 shares through the Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, and 465,604 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale of shares by an insider, it's explicitly for tax withholding purposes under a pre-arranged plan, which is a routine and expected event, not indicative of a lack of confidence in the company's future.

Positives

• The sale was pre-planned under a Rule 10b5-1 plan, indicating it was not a discretionary sale based on new material non-public information.
• The stated purpose of the sale was to cover tax withholding obligations upon RSU vesting, which is a common and expected event for executives receiving equity compensation.

Negatives

• The transaction represents a reduction in direct beneficial ownership by a key executive, although it is for a specific, non-discretionary tax purpose.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is a disclosure of an insider transaction.

Management Comments

• "Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ('RSUs') after July 15, 2023."
• "The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors.

Comparison to Industry Standards

• This document reports a standard insider transaction for tax withholding purposes, which is a common practice across all industries for executives receiving equity compensation.
• It does not contain financial or operational results that can be compared to specific industry benchmarks or competitor performance.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related transaction by a key executive and is unlikely to signal a change in company fundamentals or management's long-term view, thus minimal direct negative impact.
• Employees: The transaction relates to RSU vesting, which is part of employee compensation plans, and does not directly impact general employee operations or benefits.
• Creditors/Suppliers/Customers: No direct impact as the transaction is an internal equity management matter for an executive.

Next Steps

• The document does not specify any future actions or milestones beyond the completion of this reported transaction.

Key Dates

Recommendation

Keywords

Revolution Medicines, RVMD, Mark A. Goldsmith, SEC Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan, Biotechnology, Pharmaceuticals